MARKET

DCTH

DCTH

Delcath Sys
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.500
+0.020
+0.45%
Closed 16:00 05/26 EDT
OPEN
4.520
PREV CLOSE
4.480
HIGH
4.740
LOW
4.480
VOLUME
7.83K
TURNOVER
27.36K
52 WEEK HIGH
13.50
52 WEEK LOW
4.300
MARKET CAP
35.58M
P/E (TTM)
-1.2544
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Recap: Delcath Systems Q1 Earnings
  Delcath Systems (NASDAQ:DCTH) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 14:19
Delcath Systems Q1 EPS $(1.00) Misses $(0.88) Estimate
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.88) by 13.64 percent. This is a 3.85 percent increase over losses of $(1.04) per share from
Benzinga · 05/10 11:53
Delcath Systems GAAP EPS of -$1.00 misses by $0.12, revenue of $0.38M beats by $0.07M
Delcath Systems press release (NASDAQ:DCTH): Q1 GAAP EPS of -$1.00 misses by $0.12. Revenue of $0.38M (flat Y/Y) beats by $0.07M. On March 31, 2022, the Company had cash, cash
Seekingalpha · 05/10 11:32
Earnings Scheduled For May 10, 2022
  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
-- Earnings Flash (DCTH) DELCATH SYSTEMS Reports Q1 Loss -$1
MT Newswires · 05/10 07:54
Notable earnings before Tuesday's open
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS,
Seekingalpha · 05/09 15:06
Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the acceptance of a poster presentation at the upco...
GlobeNewswire · 05/09 12:30
More
No Data
Learn about the latest financial forecast of DCTH. Analyze the recent business situations of Delcath Sys through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average DCTH stock price target is 21.20 with a high estimate of 25.00 and a low estimate of 16.00.
High25.00
Average21.20
Low16.00
Current 4.500
EPS
Actual
Estimate
-0.78-0.58-0.39-0.19
    00
Q2 2021
    00
Q3 2021
    00
Q4 2021
    00
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 34
Institutional Holdings: 1.33M
% Owned: 16.80%
Shares Outstanding: 7.91M
TypeInstitutionsShares
Increased
6
28.38K
New
3
100.92K
Decreased
4
14.80K
Sold Out
6
180.43K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.54%
Healthcare Equipment & Supplies
+0.56%
Key Executives
Non-Executive Chairman/Independent Director
Roger Stoll
Chief Executive Officer/Director
Gerard Michel
Chief Operating Officer/Executive Vice President
John Purpura
Chief Compliance Officer/General Counsel/Secretary
David Hoffman
Vice President - Finance
Anthony Dias
Independent Director
Gilad Aharon
Independent Director
Elizabeth Czerepak
Independent Director
Steven Salamon
Independent Director
John Sylvester
No Data
No Data
About DCTH
Delcath Systems, Inc. is an oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company is a specialty pharmaceutical and medical device company developing its products. The Company's lead product candidate is HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Webull offers kinds of Delcath Systems Inc stock information, including NASDAQ:DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.